Curriculum · Metabolic and Endocrine and Diabetes Mellitus
Factitious hypoglycaemia from exogenous insulin
What it is
Factitious hypoglycemia is hypoglycemia secondary to exogenous insulin use. It matters because the clinical picture is that of insulinoma, an insulin-secreting pancreatic beta-cell tumor, and the two are told apart in the laboratory rather than at the bedside.
How it presents
The picture is recurrent attacks of symptomatic hypoglycemia in a patient without diabetes. Whipple triad holds the clinical features together: a low blood glucose level, signs or symptoms consistent with hypoglycemia, and relief of symptoms when blood glucose increases after treatment.
How it is diagnosed
C-peptide is the test that decides. It is a by-product of endogenous insulin production, from the cleavage of proinsulin into insulin, and it is not present in exogenous sources of insulin.
In insulinoma the laboratory pattern is a glucose below 55 mg/dL with raised insulin, raised C-peptide and raised proinsulin, the raised C-peptide indicating that this insulin is from an endogenous source. The interpretation of laboratory studies for hyperinsulinism sets the two side by side: proinsulin and C-peptide are normal or high in endogenous hyperinsulinism and low in exogenous hyperinsulinism, so proinsulin falls with C-peptide when the insulin comes from outside. Factitious hypoglycemia secondary to exogenous insulin use will not raise C-peptide levels. A low C-peptide therefore suggests that the patient received exogenous insulin supplies, and reduces clinical suspicion for an insulinoma or other pathology.